These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 8285805)

  • 41. Anemia management protocols and epoetin alfa administration: an algorithm approach. Case study of the anemic patient.
    Aiello J
    Nephrol Nurs J; 2002 Jun; 29(3):297-300. PubMed ID: 12164081
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Administration of Epoetin alfa. Case study of the anemic patient.
    Cutler M
    ANNA J; 1997 Aug; 24(4):459-65; quiz 466. PubMed ID: 9325701
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Management of the chronic renal failure patient receiving epoetin alfa for the treatment of anemia.
    Binkley LS
    Transplant Proc; 1991 Apr; 23(2):1831-2. PubMed ID: 2053169
    [No Abstract]   [Full Text] [Related]  

  • 45. Regarding impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis.
    Tonelli M; Owen WF; Jindal K; Winkelmayer WC; Manns B
    Kidney Int; 2004 Oct; 66(4):1712; author reply 1712-3. PubMed ID: 15458473
    [No Abstract]   [Full Text] [Related]  

  • 46. Epoetin alfa--focus on dialyzability. Case study of the anemic patient.
    Keen ML
    ANNA J; 1995 Dec; 22(6):610-3. PubMed ID: 8633909
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Case management of the anemic patient. Epoetin alfa: focus on kinetic dosing.
    Keen ML
    ANNA J; 1990 Aug; 17(4):318-9. PubMed ID: 2396859
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Advances in the management of chronic renal failure: the use of epoetin alfa in clinical practice. Proceedings of a symposium. June 6, 1989, Nashville, TN.
    Pharmacotherapy; 1990; 10(2 ( Pt 2)):1S-26S. PubMed ID: 2345707
    [No Abstract]   [Full Text] [Related]  

  • 50. Epoetin alfa: patient management issues and development through recombinant DNA technology. Part 1: Focus on Epoetin alfa patient management and recombinant DNA technology.
    Latham D; Nichols E
    ANNA J; 1990 Aug; 17(4):311-4. PubMed ID: 2396857
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes.
    Collins AJ; Brenner RM; Ofman JJ; Chi EM; Stuccio-White N; Krishnan M; Solid C; Ofsthun NJ; Lazarus JM
    Am J Kidney Dis; 2005 Sep; 46(3):481-8. PubMed ID: 16129210
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Epoetin alfa--focus on patients who are hospitalized. Case study of the anemic patient.
    Chambers JK
    ANNA J; 1996 Oct; 23(5):508-11. PubMed ID: 9069780
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anemia management in pediatric dialysis patients. Case study of the anemic patient.
    Currier H
    ANNA J; 1999 Jun; 26(3):349-52. PubMed ID: 10633609
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epoetin alfa--focus on the rehabilitation of dialysis patients. Case study of the anemic patient.
    Martin-Lester M
    ANNA J; 1996 Dec; 23(6):630-3. PubMed ID: 9069794
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Case management of the anemic patient: epoetin alfa--focus on iron supplementation.
    Kirlin LF
    ANNA J; 1993 Dec; 20(6):678-81. PubMed ID: 8267412
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Case study of the anemic patient: epoetin alfa--focus on vascular access.
    Thomas-Hawkins C
    ANNA J; 1995 Feb; 22(1):52-5. PubMed ID: 7598564
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Assessing the impact of concomitant therapies on anemia in dialysis patients. Case study of the anemic patient.
    Gregory N
    Nephrol Nurs J; 2000 Jun; 27(3):320-3; quiz 324-5. PubMed ID: 11249331
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Perspectives on the improvement of quality of life with epoetin alfa therapy.
    Lundin AP; Delano BG; Quinn-Cefaro R
    Pharmacotherapy; 1990; 10(2 ( Pt 2)):22S-26S. PubMed ID: 2345708
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Myocardial disease, anemia, and erythrocyte-stimulating proteins in chronic kidney disease.
    Foley RN
    Rev Cardiovasc Med; 2005; 6 Suppl 3():S27-34. PubMed ID: 16340936
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Managing anemia using laboratory trend analysis. Case study of the anemic patient.
    Aiello J
    ANNA J; 1999 Aug; 26(4):430-3. PubMed ID: 10838975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.